Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03RIO
|
|||
| Former ID |
DCL000383
|
|||
| Drug Name |
GSK598809
|
|||
| Indication | Drug abuse [ICD-11: 6C4G.1Z; ICD-10: F19] | Phase 2 | [1] | |
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23F4N5OS
|
|||
| Canonical SMILES |
CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=C(C=C(C=C5)C(F)(F)F)F
|
|||
| InChI |
1S/C22H23F4N5OS/c1-13-18(32-12-27-13)19-28-29-20(30(19)2)33-7-3-6-31-10-15-9-21(15,11-31)16-5-4-14(8-17(16)23)22(24,25)26/h4-5,8,12,15H,3,6-7,9-11H2,1-2H3
|
|||
| InChIKey |
ZKRWPAYTJMRKLJ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D3 receptor (D3R) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Dopaminergic synapse | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01188967) Effectiveness of GSK598809, a Selective D3 Antagonist, Added to Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation and Prevention of Very Early Relapse to Smoking. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.